Skip to content
    SPRY
    Earnings call· Jun 2026(Q2 FY26)

    ARS Pharmaceuticals Q2 FY26 earnings call SPRY

    Aug 13, 2026 Source

    Executive summary

    ARS Pharmaceuticals Q2 FY26 — Strategic Shift to Targeted Commercialization and Financial Discipline

    ARS Pharmaceuticals, under new CEO Don Casale, is implementing a strategic pivot towards disciplined, provider-targeted commercial execution for NEPI, coupled with significant financial optimization to achieve cash flow break-even by late 2027. This shift involves reducing broad direct-to-consumer spending and focusing on high-value prescribers, while also advancing the intranasal epinephrine platform into chronic spontaneous urticaria (CSU) with a Phase 2b trial readout expected in Q1 2027.

    Highlights

    5

    • US net product revenue was $26.2 million in Q2 FY26.

    • Total US market share for NEPI reached 5%, doubling from 2.5% in Q2 FY25.

    • NEPI market share within the field sales targeted universe increased to 8%, up from 4% in Q2 FY25.

    • Over 16,000 unique NEPI prescribers in Q2 FY26, representing more than a three-fold increase from Q2 FY25.

    • The company projects a path to cash flow break-even by the end of 2027.

    Concerns

    2

    • Total operating expenses were $95.1 million, including $77.6 million in SG&A, driven by a prior costly broad consumer awareness strategy.

    • Interim data readout from the Phase 2b CSU trial is now expected in Q1 2027, delayed from the previously projected end of 2026.

    Guidance & targets

    4
    CategoryTargetConfidence
    Adjusted aggregate SG&A and R&D expenses
    $114 million to $126 million
    high materiality
    High
    Cash-based SG&A and R&D expenses
    $100 million to $110 million
    high materiality
    High
    Cash flow break-even
    By the end of 2027
    high materiality
    High
    Gross margin
    Improve over time
    medium materiality
    Medium

    Operational metrics

    13
    US net product revenue
    $26.2 million
    Q2 FY26

    Reported for the second quarter.

    Total revenue
    $33.7 million
    Q2 FY26

    Reflecting a combination of net product, collaboration, and supply revenue.

    Total operating expenses
    $95.1 million
    Q2 FY26

    Includes cost of goods sold and SG&A.

    Cost of goods sold
    $12.8 million
    Q2 FY26

    Included in total operating expenses.

    SG&A expenses
    $77.6 million
    Q2 FY26

    Driven by prior commercial strategy emphasizing broad consumer awareness.

    Cash, cash equivalents, and short-term investments
    $143.8 million
    Q2 FY26 end

    Company ended the second quarter with this balance. Transcription error corrected from 'billion' to 'million' based on financial context.

    Gross-to-net
    approaching 50%
    future

    Anticipated to ebb and flow depending on segment mix, but comfortable with this range for future profitability.

    Gross margin
    62%
    Q2 FY26

    Lower than projected, but expected to improve over time, especially into 2027.

    Gross margin
    64%
    YTD FY26

    Year-to-date figure, also lower than projected.

    Unique NEPI prescribers
    16,000+more than a three-fold increase from Q2 FY25
    Q2 FY26

    Indicates growing adoption among healthcare professionals.

    Commercial coverage for NEPI
    90%
    current

    Represents the percentage of commercial lives covered.

    Commercial coverage for NEPI without prior authorization
    57%
    current

    Percentage of commercial coverage that does not require prior authorization.

    Sales force focus on highest value prescribers
    44%
    current

    Represents the portion of the total market opportunity targeted by the sales force.

    Industry KPIs

    1
    MetricValueDetails
    Therapeutic drug market share5%%

    Deals & partnerships

    1
    UnknownLicense agreement for worldwide rights to certain intellectual property (IP)

    This agreement provides an opportunity for the company to consider a line extension for the NEPI franchise.

    Risks & headwinds

    3
    High cost of prior broad direct-to-consumer advertising strategyQ2 FY26

    $77.6 million in SG&A for Q2 FY26

    Mitigation: Implementing rigorous strategic cost optimization, significantly reducing SG&A, and shifting to a targeted provider commercial strategy.

    Delay in CSU Phase 2b interim data readoutQ1 2027

    Interim readout now expected in Q1 2027, previously end of 2026

    Mitigation: The delay is due to the trial design requiring patients to log three separate flare episodes, which takes real-world time; management states this does not change the program's value.

    Entrenched provider prescribing habits for auto-injectorsOngoing

    NEPI market share is 8% in the targeted universe versus 1% in the non-targeted universe, indicating resistance to change.

    Mitigation: Focusing on high-level frequency with the right message, utilizing a fully deployed sales team for blocking and tackling execution, and educating providers on NEPI's value proposition and the problem it solves.

    What to watch in Q3 FY26

    4

    NEPI market share in targeted universe

    Successive quarters
    Current8%
    TargetSteady market share gains

    Why it matters

    Indicates the effectiveness of the new targeted commercial strategy and the impact of the fully deployed sales force.

    Looking ahead, we expect steady market share gains over successive quarters, not an overnight We are focused on driving the next phase of growth with disciplined commercial execution, clear accountability, and prudent expense management.

    Q&A highlights

    6

    Can you discuss the gross-to-net evolution, product margins, and what drives them? Also, how do you plan to substantially increase the 8% market share in field-targeted accounts?

    Gross-to-net is anticipated to be around 50%. Gross margin was 62% in Q2 (64% YTD), lower due to short-dated product reserves, manufacturing inefficiencies, and ex-US launch costs, but expected to improve into 2027. Market share growth in targeted accounts will be driven by the fully deployed sales team, evolving messaging campaigns to engage the entire office (physicians, nurses, MAs), and consistent execution.

    “So our gross margin was about, excuse me, 62% in Q2 and a little over 64% year-to-date. And that was lower than we project going forward for a few reasons. One is the establishment of some reserves for short-dated product, some manufacturing inefficiencies as we continue to scale production, and costs for the ex-US product launches.”

    asked by Joshua Schimmer · answered by Donn Casale

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Priorities Under New CEO

    Don Casale, in his first earnings call as CEO, outlined three core strategic priorities: targeted provider commercial execution for NEPI, rigorous financial discipline with OpEx control, and pipeline expansion starting with the CSU program. This new approach signifies a fundamental change in how the company manages its business and allocates capital, moving towards building a profitable NEPI franchise with predictable cash flow.

    02

    NEPI Commercial Strategy Shift

    The company is pivoting from broad direct-to-consumer digital advertising, which was costly and less effective in a 'prevention-based' market, to a more efficient, provider-targeted commercial strategy. The focus is on changing long-established provider prescribing habits through repeated, high-quality clinical interactions by a fully deployed sales team. This team will target high-volume prescribers, aiming to increase NEPI's market share from its current 8% in the targeted universe.

    03

    Financial Discipline and Cost Optimization

    ARS Pharma is implementing a rigorous strategic cost optimization framework, significantly reducing SG&A expenses. Cash-based SG&A and R&D expenses for H2 2026 are expected to be $100 million to $110 million, representing a more than 40% reduction in cash-based SG&A from H1 2026. This spending trend is expected to continue throughout 2027, supporting the company's path to cash flow break-even by the end of 2027.

    04

    CSU Program Advancement and Timeline Shift

    The intranasal epinephrine platform is being extended to chronic spontaneous urticaria (CSU), a meaningful market with a major unmet public health need for acute flare management. The interim data readout from the Phase 2b trial, previously projected by the end of 2026, is now expected in Q1 2027. This delay is attributed to the trial design requiring patients to experience and log three separate flare episodes, which takes real-world time for valid data collection.

    05

    Reimbursement and Provider Conviction

    While NEPI has strong commercial coverage (90% with 57% without prior authorization), management emphasizes that securing formulary position is only the first step. The highest operational priority is building provider conviction, ensuring healthcare providers appreciate and acknowledge the clinical gap NEPI fills. This conviction is crucial for translating coverage into actual prescriptions and driving market share growth.

    06

    Commercial Leadership and Sales Force Expansion

    Meg Smith has been appointed as the new Chief Commercial Officer to lead the disciplined commercial strategy, bringing a track record of combining disciplined investment with operational accountability. The field sales organization has completed its expansion and will primarily focus on the highest value prescribers, which represent 44% of the total market opportunity, to drive market share gains.

    AI-generated summary of the company’s earnings call. Not investment advice.